KEY TAKEWAYS Blood biomarker tests have reached levels of accuracy on par with more intrusive diagnostic tests for Alzheimer’s disease such as cerebrospinal fluid analysis (CSF) and PET imaging. Blood … Read More
Preclinical Alzheimer’s Disease (PCAD)
KEY TAKEWAYS Pre-clinical Alzheimer’s disease (PCAD) is a condition in which Alzheimer’s disease in the form of abnormal amyloid protein concentrations form in the brain before symptoms of Alzheimer’s disease … Read More
Equity issues for Alzheimer’s disease
KEY TAKEWAYS Significant disparities persist in Alzheimer’s detection, diagnosis, treatment, and monitoring, disproportionately affecting racial/ethnic minorities, women, rural, low socioeconomic groups, and persons with Down Syndrome. Addressing disparities in healthcare … Read More
Reengineering Alzheimer’s Disease Management: Executive Brief
The approval of disease-modifying therapies for early, symptomatic Alzheimer’s disease is raising hope for patients and caregivers. And promising new therapeutic and diagnostic capabilities are expected in the next five … Read More
- Page 2 of 2
- 1
- 2